Lux Venture Partners V, LLC

CIK: 0001698118

Transaction Breakdown

Open Market Buys (P)2 (40.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)0 (0.0%)

Compensation grants

Other (G, F, J, C, D, …)3 (60.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

EIKN

Eikon Therapeutics, Inc.

10% Owner

Discretionary Trading P&L

Holdings

Transaction History (5 total)

EIKN
Eikon Therapeutics, Inc.
Feb 6, 2026
Conversion(C)
Indirect
2.4M shares-
EIKN
Eikon Therapeutics, Inc.
Feb 6, 2026
Conversion(C)
Indirect
1.2M shares-
EIKN
Eikon Therapeutics, Inc.
Feb 6, 2026
Conversion(C)
Indirect
2.2M shares-
EIKN
Eikon Therapeutics, Inc.
Feb 4, 2026
Purchase(P)
Indirect
138.9K shares at avg. $18.00$2.5M
EIKN
Eikon Therapeutics, Inc.
Feb 4, 2026
Purchase(P)
Indirect
138.9K shares at avg. $18.00$2.5M

		Type	Shares	Price		Ownership
Feb 6, 2026	EIKN Eikon Therapeutics, Inc.	Conversion(C)	2,387,705	-	$0	Indirect
Feb 6, 2026	EIKN Eikon Therapeutics, Inc.	Conversion(C)	1,151,540	-	$0	Indirect
Feb 6, 2026	EIKN Eikon Therapeutics, Inc.	Conversion(C)	2,155,765	-	$0	Indirect
Feb 4, 2026	EIKN Eikon Therapeutics, Inc.	Purchase(P)	138,888	$18.00	$2,499,984	Indirect
Feb 4, 2026	EIKN Eikon Therapeutics, Inc.	Purchase(P)	138,888	$18.00	$2,499,984	Indirect

1-5 of 5 transactions

About Lux Venture Partners V, LLC

Lux Venture Partners V, LLC (SEC CIK 0001698118) files insider reports with the SEC as 10% Owner of Eikon Therapeutics, Inc. (EIKN).

Signal8 holds 2 ownership filings by Lux Venture Partners V, LLC (1 Form 3, 1 Form 4), filed between Feb 4, 2026 and Feb 6, 2026. Those filings report 5 transactions, from Feb 4, 2026 to Feb 6, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Lux Venture Partners V, LLC's filings is in NEW YORK, NY.

Recent filings by Lux Venture Partners V, LLC

Feb 6, 2026: Conversions of EIKN shares (3 lines, Form 4, code C).
Feb 4, 2026: Open-market purchases of EIKN shares (2 lines, Form 4, code P).

Other insiders filing for Eikon Therapeutics, Inc. (EIKN)

Column Group IV GP, LP, 10% Owner
Francisco Ma. Fatima, Director
Klobuchar Michael A, Chief Operating Officer
Huffines Robert Luther, Director
FRAZIER KENNETH C, Director
PERLMUTTER ROGER M

How to read Form 4 transaction codes